ArticleCanadian liver journal2025
The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populations.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hepatitis C virus (HCV) affects approximately 214,000 Canadians. While the availability of safe, effective direct-acting antivirals (DAA) has led to decreased rates of chronic HCV infection and increased treatment uptake, major challenges to achieving HCV elimination remain. This report summarizes key findings from the 14th Canadian Symposium on Hepatitis C Virus, which focused on advancing equitable strategies for HCV elimination through multidisciplinary dialogue. Methods: The symposium was titled "From Research Breakthroughs to Equitable Healthcare for Priority Populations," and brought together researchers, clinicians, policymakers, and community stakeholders to advance Canada's efforts toward HCV elimination by 2030. Hosted in Quebec City by the Canadian Network on Hepatitis C (CanHepC), the symposium highlighted key findings across biomedical, clinical, population health, and health services research. Results: Biomedical presentations emphasized progress in HCV vaccine development, host-virus interactions, and T-cell exhaustion mechanisms. Notable findings included novel insights into immune escape pathways, host-targeted antivirals, and epigenetic barriers to T-cell reinvigoration. Clinical and population health sessions addressed inequities in HCV prevention and care for women and pregnant people, incarcerated individuals, and people who use drugs. Presenters showcased the impact of decentralized point-of-care HCV RNA testing on diagnosis and linkage to treatment in high-risk populations, including those with unstable housing. Implementation-focused discussions included updates to the national Blueprint to Inform HCV Elimination and strategies to scale nurse-led and community-based interventions. Conclusions: The symposium emphasized the importance of integrating scientific advances with community-driven and equity-focused actions, particularly for priority populations experiencing systemic barriers to care. Through inclusive dialogue and multidisciplinary knowledge exchange, the symposium reaffirmed CanHepC's commitment to bridging research and practice to accelerate the path toward HCV elimination in Canada.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.